MedAssurant, which seeks to better use healthcare data to drive clinical outcomes and financial performance, has announced an innovation that's shown to increase analytical process runs by a factor of 2,000 over methodologies previously available.
The implementation of MedAssurant's Quality Spectrum Cluster Logic (QSCL) technology, a proprietary analytical data structure designed to enable acceleration of complex healthcare data analyses, is a 'milestone' that could be a boon for payers, providers and medical and pharmaceutical researchers, say executives.
"This is a significant advancement in healthcare data analytical power above any system or platform available in today's marketplace," said Greg Jones, chief technology officer at MedAssurant. "The unique design, enabled through a proprietary, hardware-agnostic MPP (Massively Parallel Processing) engine, allows for the use of unique data structures combined with optimized processing algorithms to yield industry-leading performance.
The result of more than four years of research and development, QSCL offers straightforward measure design and advanced querying performance. In parallel with the development of QSCL, MedAssurant has optimized the current analytical toolsets that drive the company's system processes and insight into healthcare data.
Additionally, MedAssurant has integrated its Medical Outcomes Research for Effectiveness & Economics Registry (MORE2 Registry) dataset into the QSCL platform. The MORE2 Registry is an industry-leading healthcare data asset composed of more than 3.9 billion medical events from more than 76 million patients, 295,000 physicians and 185,000 clinical facilities throughout the United States. Through the power of these combined capabilities, MedAssurant can run highly sophisticated clinical analytics across billions of events within minutes – a process that would have previously required several weeks to complete.
[Medicaid Health Plans of America recently enlisted MedAssurant to put its data analytics to work to increase quality and improve outcomes for the medically underserved. See: MHPA taps MedAssurant to promote best practices for Medicaid plans.]
"In addition to expanding the company's client solution arsenal, QSCL is a clear demonstration of how MedAssurant is advancing the core technologies available to empower a more advanced generation of technology-enabled solutions in healthcare," said Jones.
[AHIP has also put MedAssurant's technologies to work to help to translate data into more affordable and quality care for patients. See: AHIP receives research support boost.]
Said Cary Sennett, MD, MedAssurant's chief medical officer and head of the company's Clinical & Statistical research team: "In a landscape where comparative effectiveness research (CER), outcomes analyses, pharmacovigilence and other forms of healthcare insight have become increasingly critical, our ability to run complex algorithms at such speeds, across large datasets will further advance MedAssurant's capabilities."
Beyond accelerating analytics applied to client needs, the improved performance will further empower MedAssurant's product design, development and operational capabilities.
"As part of our design-build-operate strategy, MedAssurant leverages datasets through applications of population simulations, matched peer cohort analyses, intervention effectiveness design, relative comparative metrics development and a host of processes which provide us with a more rapid path for product design and enhancement," said Dan Rizzo, MedAssurant's chief product officer. "The achievement of QSCL will dramatically accelerate this – unlocking new opportunities and yielding our clients even greater value going forward."